Back to top
more

Fulcrum Therapeutics (FULC)

(Real Time Quote from BATS)

$3.32 USD

3.32
644,026

+0.06 (1.84%)

Updated Nov 5, 2024 03:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab

by Zacks Equity Research

Immunovant stock rises on mid-stage study data of batoclimab for Graves' Disease, showing superior efficacy compared to anti-thyroid drug therapy options.

Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient

by Zacks Equity Research

HOTH stock soars on superior efficacy data from the first patient treated with the lead candidate, HT-001, suffering from EGFRI-related skin toxicities.

Novartis to License VYGR's Capsid for Gene Therapy in Neurology

by Zacks Equity Research

NVS has decided to license a novel capsid generated from Voyager's TRACER platform for use in a gene therapy program against an undisclosed rare neurologic disease target.

FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up

by Zacks Equity Research

The FDA accepts Axsome's resubmission of the NDA for AXS-07 for the acute treatment of migraine. A decision is due on Jan. 31, 2025. Shares rise.

BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years

by Zacks Equity Research

BMRN divulges ambitious plans for business growth over the next 10 years. It expects yearly sales to grow at a mid-teen rate through 2034.

Biogen's Phase II/III SMA Study for Higher Spinraza Dose Meets Goals

by Zacks Equity Research

BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.

Affimed Appoints New CEO, Shares Fall on Leadership Change

by Zacks Equity Research

AFMD appoints Shawn M. Leland as the company's new chief executive officer. Stock falls on the news.

Recursion Stock Down Despite Meeting Goal in Brain Disease Study

by Zacks Equity Research

RXRX plummets on mixed results from the mid-stage study of its lead candidate, REC-994, for treating a rare neurovascular condition.

Corcept Shares Rise More Than 45% in Six Months: Here's Why

by Zacks Equity Research

CORT's Cushing's syndrome drug, Korlym, has been performing well. The NDA for lead candidate, relacorilant, in Cushing's syndrome will be filed shortly.

Amneal Stock Rises 29% in a Month on Upbeat Regulatory Updates

by Zacks Equity Research

AMRX stock gains 29.3% in a month due to the FDA's approval of Parkinson's Disease drug, Crexont.

ALNY Down Despite Positive Data From Heart Disease Drug Study

by Zacks Equity Research

Alnylam presents detailed data from the HELIOS-B study, seeking to expand Amvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy.

Krystal Biotech Stock Surges 21.9% in 3 Months: More Room to Grow?

by Zacks Equity Research

KRYS has gained 21.9% in the past three months on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.

JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab

by Zacks Equity Research

The Johnson & Johnson filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.

Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data

by Zacks Equity Research

MRK made this decision after an independent committee pointed out that Keytruda did not show improvement in certain types of lung and skin cancers.

EBS Stock Rises on FDA Nod for ACAM2000 in Mpox Indication

by Zacks Equity Research

The FDA approves Emergent BioSolutions' sBLA seeking a label expansion of ACAM2000 for the mpox indication. Stock rises in pre-market trading.

SWTX's NDA for Rare Tumor Drug Gets Priority Review From FDA

by Zacks Equity Research

The FDA accepts and grants priority review to SpringWorks' NDA for mirdametinib for treating neurofibromatosis type 1-associated plexiform neurofibromas.

Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results

by Zacks Equity Research

Though data from a mid-stage study shows that treatment with NBIX's schizophrenia drug is effective, results lag behind drugs being developed by its peers.

J&J's Rybrevant Receives EU Approval for Expanded Use in NSCLC

by Zacks Equity Research

The European Commission approves JNJ's Rybrevant in combination with chemotherapy for treating EGFR-mutated NSCLC following failure of prior therapy.

MRK Begins 2nd Phase III Study on Rare Blood Disorder Candidate

by Zacks Equity Research

Merck begins the second phase III study on its LSD1 inhibitor, bomedemstat, for treating certain patients with essential thrombocythemia, a rare blood disorder.

Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs

by Zacks Equity Research

PFE's digital pharmacy aims to provide patients easy access to its medicines for COVID-19, migraine and other conditions.

Addex Stock Soars on Crucial Update From Indivior Research Deal

by Zacks Equity Research

ADXN gains 55% on a crucial update from its GABAB PAM research collaboration with INDV. Both companies pick pre-clinical compounds for IND-enabling studies.

Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review

by Zacks Equity Research

SLNO stock gains 6.3% as FDA accepts regulatory filing for lead candidate, DCCR, to treat hyperphagia associated with PWS under Priority Review.

Ocugen to Begin Phase III Study on Eye Drug in Canada, Stock Up

by Zacks Equity Research

OCGN receives Health Canada's No Objection Letter to begin a phase III study on OCU400 for treating retinitis pigmentosa. Shares rise.

Insmed Stock Surges 168% in the Past Six Months: Here's Why

by Zacks Equity Research

Shares of INSM soar after it reports positive data from two clinical studies that highlight its encouraging progress with its lung disorder drugs.

Rhythm Stock Up as FDA Accepts Obesity Drug sNDA for Younger Kids

by Zacks Equity Research

RYTM gains 8% as FDA accepts Imcivree sNDA seeking label expansion of the drug to treat obesity in kids as young as two years old.